TICKERNERD
Menu
OKUROKURHealthcare · Biotechnology

OKUR Stock Forecast: OnKure Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 24 Aug 2026
$3.89
−1.27% on the day

The 6 Wall Street analysts covering OnKure Therapeutics, Inc. hold a median 12-month price target of $15 — +285.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 55 of 100 as at 22 Aug 2026 — in the upper half.

Market cap
$157.5M
Ticker Nerd rank
55 / 100
Median analyst target
$15
Analysts covering
6
Revenue$0.0
Operating income−$16.9M
Net income−$15.3M
Free cash flow−$10.4M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−5.4%
1M
−5.6%
YTD
+34.1%
1Y
+37.5%
From 52W high
−26.2%
From 52W low
+67.7%
$2.32
$5.27
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

OKUR stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores OnKure Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
55 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
83
Size
71
Momentum
70
Revisions
69
Quality
60
Growth
59
Accruals
50
Issuance
18
Value
11

Volatility (83): The share price has been relatively steady.

Value (11): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

OKUR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on OKUR, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00$20.00Oct 25Jan 26Apr 26Jul 26OKURHigh $21Median $15Low $11

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says6 analysts
5 Buy1 Hold0 Sell
Low $11Median $15High $21

The green dot is the last close — the median target sits +285.6% from it.

Recent analyst actionsNewest first

Of the 13 most recent actions, 0 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
14 Aug 2026OppenheimerReiteratesOutperform$30 → $14
20 July 2026HC Wainwright & Co.MaintainsBuy$27 → $21
20 July 2026HC Wainwright & Co.MaintainsBuy—
16 Mar 2026HC Wainwright & Co.MaintainsBuy$34 → $27
16 Mar 2026HC Wainwright & Co.MaintainsBuy—
26 Aug 2025HC Wainwright & Co.ReiteratesBuy—
18 Mar 2025HC Wainwright & Co.MaintainsBuy—
11 Mar 2025OppenheimerMaintainsOutperform—
28 Jan 2025Jones TradingInitiatesBuy—
5 Dec 2024Leerink PartnersInitiatesOutperform—
8 Nov 2024HC Wainwright & Co.ReiteratesBuy—
17 Oct 2024HC Wainwright & Co.AssumesBuy$40
10 Oct 2024OppenheimerInitiatesOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. OKUR appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

OKUR vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 24 Aug 2026, OnKure Therapeutics, Inc. returned +37.5% against +19.6% for the S&P 500, dividends included.

OKUR vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160180Oct 25Jan 26Apr 26Jul 26OKURS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

OKUR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

OnKure Therapeutics, Inc. (OKUR) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
62.1×

Cheaper than 12% of US stocks

Price / sales
—
Price / book
0.9×

Cheaper than 76% of US stocks

EV / EBITDA
0.3×

Cheaper than 59% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−46.9%

Higher than 22% of US stocks

Return on assets
−29.3%

Higher than 14% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

OnKure Therapeutics, Inc. (OKUR) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • OnKure Therapeutics, Inc. has a market value of $157.5M and an enterprise value of −$17.9M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$58.7M.

  • Diluted earnings per share, trailing twelve months: $−3.50.

  • Free cash flow in the twelve months to 30 June 2026: −$47.9M.

  • Shares outstanding: 40.5M.

  • Trailing P/E: 62.1×; forward P/E: −2.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • OnKure Therapeutics, Inc. employs 45 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 25 Aug 2026

Data provided by Twelve Data

Peers

OKUR vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
OKUROnKure Therapeutics, Inc.$157.5M
55
OTLKOutlook Therapeutics, Inc.$157.6M
4
MENSJyong Biotech Ltd.$161.8M
3
TNYATenaya Therapeutics, Inc.$151.0M
39
UNCYUnicycive Therapeutics, Inc.$150.3M
35
CNTNCanton Strategic Holdings, Inc.$168.9M
12
MDWDMediWound Ltd.$169.4M
29

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own OnKure Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest OKUR news & analysis

OnKure Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights

GlobeNewsWire · 4 Aug 2026neutral

OnKure Therapeutics reported its second quarter 2026 financial results and provided business highlights. The company noted it is executing IND-enabling activities for next-generation PI3Kα pan-mutant selective candidates OKI-345 (breast cancer) and OKI-355 (vascular anomalies), with IND submissions planned for the first half of 2027.

Why it matters — The update signals that OnKure is advancing two next-generation pipeline candidates toward planned IND submissions, a key step for OKUR watchers tracking the company's clinical development progress.

FAQ

Frequently asked questions about OKUR stock

What is the OKUR stock price forecast for 2026-2027?

The 6 Wall Street analysts covering OnKure Therapeutics, Inc. have a median 12-month price target of $15, with estimates ranging from $11 to $21. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is OKUR stock a buy right now?

Of the 6 analysts covering OnKure Therapeutics, Inc., 5 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks OnKure Therapeutics, Inc. 55 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank OKUR?

As at 22 Aug 2026, OnKure Therapeutics, Inc. ranks 55 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (83 of 100).

Will OKUR stock go up?

No one can know that. What the data says: the median 12-month target from 6 analysts implies +285.6% from the last close, and Ticker Nerd's factor model ranks OnKure Therapeutics, Inc. 55 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the OKUR stock forecast for 2030?

No analyst covering OnKure Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OKUR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $11 to $21 over the next 12 months.

How has OKUR stock performed over the past year?

OnKure Therapeutics, Inc. returned +37.5% over the 12 months to 24 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does OnKure Therapeutics, Inc. do?

OnKure Therapeutics Inc. is a biotechnology company focused on the discovery and development of novel therapies for cancer treatment.

What is the latest news on OKUR?

The most recent item we track (GlobeNewsWire, 4 Aug 2026): "OnKure Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights". OnKure Therapeutics reported its second quarter 2026 financial results and provided business highlights. The company noted it is executing IND-enabling activities for next-generation PI3Kα pan-mutant selective candidates OKI-345 (breast cancer) and OKI-355 (vascular anomalies), with IND submissions planned for the first half of 2027.

Company

About OnKure Therapeutics, Inc.

OnKure Therapeutics Inc. is a biotechnology company focused on the discovery and development of novel therapies for cancer treatment. The primary aim of OnKure is to advance precision oncology, targeting specific molecular characteristics of cancer to improve treatment outcomes. The company's research is central to the field of epigenetics and targeted therapies, seeking to develop drug candidates that modify gene expression patterns linked to cancer progression. These efforts are pivotal in addressing unmet needs within the oncology sector, which is continually evolving with new biological insights and technological advancements. OnKure's role in the market is significant as it contributes to the diversification and innovation of available cancer therapies, potentially offering more effective treatment options for patients. As a player in the biotechnology industry, OnKure Therapeutics engages in partnerships, collaborations, and clinical trials, striving to bring its drug candidates from the lab to the clinic and eventually to the market as viable treatment options. Its work underscores the critical importance of biotechnology companies in advancing medical science and expanding available therapeutic solutions.

CEO Dr. Nicholas A. Saccomano Ph.D. · 45 employees · United States · https://onkuretherapeutics.com